The global neurorehabilitation devices market size reached USD 2.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.2% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 2.0 Billion |
Market Forecast in 2033
|
USD 4.5 Billion |
Market Growth Rate 2025-2033 | 9.2% |
Neurorehabilitation devices refer to the equipment used for examination of the brain and central nervous system (CNS). Some of the commonly used devices include neurorobotic systems, non-invasive brain stimulators, neuroprosthetics, brain-computer interfaces and wearable devices. These devices assist in the diagnosis and treatment of a disease, disorder or injury in the nervous system of the patient. They facilitate in re-learning motor skills and optimal recovery from neurological disorders, such as Parkinson’s disease, and cardiovascular stroke. As a result, neurorehabilitation devices find extensive applications across various clinics, cognitive care and research institutes and healthcare centers.
The increasing prevalence of neurological diseases, such as multiple sclerosis, Parkinson’s disease and cerebral palsy, is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. Neurorehabilitation devices aid in deploying diversified electric signals to multiple fibers of the spinal cord for the recovery of limb movements. Additionally, various technological advancements, such as the gamification of rehabilitation activities through virtual reality (VR), robotics and artificial intelligence (AI), that aid in promoting recovery are acting as other growth-inducing factors. In line with this, the utilization of novel multi-electrode stimulation for the treatment of spinal cord injuries is also contributing to the market growth. Other factors, including rising healthcare expenditure capacities of the masses, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurorehabilitation devices market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product type, application and end user.
Breakup by Product Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biometrics Ltd, Bioness Inc., Bionik Laboratories Corp, BioXtreme Ltd., Boston Scientific Corporation, Ectron Ltd, Ekso Bionics, Hocoma AG (DIH International Limited), Kinestica, Kinova Inc., Medtronic plc, Saebo Inc and Tyromotion GmbH.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product Type, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Biometrics Ltd, Bioness Inc., Bionik Laboratories Corp, BioXtreme Ltd., Boston Scientific Corporation, Ectron Ltd, Ekso Bionics, Hocoma AG (DIH International Limited), Kinestica, Kinova Inc., Medtronic plc, Saebo Inc and Tyromotion GmbH |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global neurorehabilitation devices market was valued at USD 2.0 Billion in 2024.
We expect the global neurorehabilitation devices market to exhibit a CAGR of 9.2% during 2025-2033.
The increasing prevalence of neurological diseases, such as multiple sclerosis, Parkinson’s disease, cerebral palsy, etc., is primarily driving the global neurorehabilitation devices market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective brain and Central Nervous System (CNS) treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for neurorehabilitation devices.
Based on the product type, the global neurorehabilitation devices market can be categorized into neurorobotic devices, wearable devices, non-invasive stimulators, and brain-computer interface. Currently, non-invasive stimulators account for the majority of the global market share.
Based on the application, the global neurorehabilitation devices market has been segregated into stroke, multiple sclerosis, Parkinson’s disease, cerebral palsy, and others. Among these, stroke currently exhibits a clear dominance in the market.
Based on the end user, the global neurorehabilitation devices market can be bifurcated into hospitals and clinics, cognitive care centers, and others. Currently, hospitals and clinics hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global neurorehabilitation devices market include Biometrics Ltd, Bioness Inc., Bionik Laboratories Corp, BioXtreme Ltd., Boston Scientific Corporation, Ectron Ltd, Ekso Bionics, Hocoma AG (DIH International Limited), Kinestica, Kinova Inc., Medtronic plc, Saebo Inc, and Tyromotion GmbH.